Biomea Fusion To Report Results From Phase I GLP-131 Clinical Study Evaluating BMF-650, Investigational Next-Gen Oral Small-Molecule GLP-1 Receptor Agonist, On October 13
Biomea Fusion Says Topline Data From Phase 1 Obesity Trial Of BMF-650 Now Expected In October, Pushed From Q3
Biomea Fusion, Inc. (BMEA) Presents at H.C. Wainwright 28th Annual Global Investment Conference - Slideshow (NASDAQ:BMEA) 2026-09-16